Claims for Patent: 12,343,372

Summary for Patent: 12,343,372

Title:	Desmopressin oral compositions
Abstract:	Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.
Inventor(s):	Yu-Hsing Tu, Kalyan Kathala, Romona BHATTACHARYA, Yingjun Fan, Ashok Perumal
Assignee:	Tulex Pharmaceuticals Inc
Application Number:	US18/955,504
Patent Claims:	1. A method of treating a disease or condition, or symptoms thereof, comprising administering a therapeutically effective amount of a liquid pharmaceutical composition to a subject in need thereof, the liquid pharmaceutical composition comprising: a) desmopressin acetate; b) a two-component, dual-functional, preservative-buffer system that comprises sodium benzoate and benzoic acid; and c) water; wherein the disease or condition, or symptoms thereof is selected from the group consisting of: diabetes insipidus, nocturnal enuresis, nocturia, hypothalamic injury-induced obesity (HIO), hemophilia A, von willebrand disease, postoperative bleeding, polyurea, and high blood urea levels. 2. The method of claim 1, wherein desmopressin acetate is present in the liquid pharmaceutical composition in an amount of from about 0.01 mg/mL to about 0.1 mg/mL. 3. The method of claim 1, wherein desmopressin acetate is present in the liquid pharmaceutical composition in an amount of about 0.05 mg/mL. 4. The method of claim 1, wherein benzoic acid is present in the liquid pharmaceutical composition in an amount of from about 0.005% w/v to about 0.1% w/v. 5. The method of claim 1, wherein benzoic acid is present in the liquid pharmaceutical composition in an amount of from about 0.02% w/v to about 0.05% w/v. 6. The method of claim 1, wherein sodium benzoate is present in the liquid pharmaceutical composition in an amount of from about 0.01% w/v to about 0.6% w/v. 7. The method of claim 1, wherein sodium benzoate is present in the liquid pharmaceutical composition in an amount of from about 0.15% w/v to about 0.32% w/v. 8. The method of claim 1, wherein benzoic acid and sodium benzoate are present in the liquid pharmaceutical composition in an amount of from about 0.25% w/v to about 0.35% w/v. 9. The method of claim 1, wherein the liquid pharmaceutical composition further comprises a preservative, and wherein the preservative comprises an antimicrobial agent, a chelating agent, an antioxidant, or a combination thereof. 10. The method of claim 9, wherein the preservative comprises a paraben or mixture of parabens. 11. The method of claim 1, wherein the liquid pharmaceutical composition has a pH that is from about 4.0 to about 6.0. 12. The method of claim 1, wherein the liquid pharmaceutical composition comprises: a) desmopressin acetate in an amount of from about 0.01 mg/mL to about 0.1 mg/mL; b) sodium benzoate in an amount of from about 0.18% w/v to about 0.4% w/v; c) benzoic acid in an amount of from about 0.02% w/v to about 0.1% w/v; and d) water. 13. The method of claim 1, wherein the liquid pharmaceutical composition comprises: a) desmopressin acetate in an amount of from about 0.025 mg/mL to about 0.075 mg/mL; b) sodium benzoate in an amount of from about 0.2% w/v to about 0.35% w/v; c) benzoic acid in an amount of from about 0.03% w/v to about 0.04% w/v; and d) water. 14. The method of claim 1, wherein the liquid pharmaceutical composition comprises: a) desmopressin acetate in an amount of about 0.05 mg/mL; b) sodium benzoate in an amount of about 0.285% w/v; c) benzoic acid in an amount of about 0.034% w/v; and d) water. 15. The method of claim 1, wherein the liquid pharmaceutical composition consists essentially of: a) desmopressin acetate in an amount of about 0.05 mg/ml; b) sodium benzoate in an amount of about 0.285% w/v; c) benzoic acid in an amount of about 0.034% w/v; and d) water. 16. The method of claim 1, wherein the liquid pharmaceutical composition consists of: a) desmopressin acetate in an amount of about 0.05 mg/ml; b) sodium benzoate in an amount of about 0.285% w/v; c) benzoic acid in an amount of about 0.034% w/v; and d) water. 17. The method of claim 1, wherein the liquid pharmaceutical composition is ready-to-use without dilution or addition of any further components to the liquid pharmaceutical composition. 18. The method of claim 1, wherein the liquid pharmaceutical composition contains no more than 5% wt of total impurities and not more than 1% wt of each of the following impurities: [Asp5]desmopressin, [Glu4]desmopressin, [Gly9OH]desmopressin, [L-Arg8] desmopressin, [Gln4(Acm)]desmopressin, [Asn5(Acm)]desmopressin, and [Gly9N(CH3)2]desmopressin after stored at 40° C.±2° C. and 75±5% RH humidity for 6 months, wherein an amount of impurities is determined according to high-performance liquid chromatography (HPLC) method. 19. The method of claim 1, wherein the liquid pharmaceutical composition retains at least 90% wt of the initial desmopressin acetate amount after stored at 40° C.±2° C. and 75±5% RH for 6 months, wherein an amount of desmopressin acetate is determined according to high-performance liquid chromatography (HPLC) method. 20. The method of claim 1, wherein the liquid pharmaceutical composition exhibits a bioavailability that is bioequivalent to a reference oral tablet composition comprising desmopressin acetate, when measured as the total area under the curve (AUC) after oral administration or when measured as Cmax after oral administration. 21. The method of claim 1, wherein the liquid pharmaceutical composition has a pH that is about 5.0. 22. The method of claim 1, wherein the disease or condition, or symptoms thereof is diabetes insipidus. 23. The method of claim 1, wherein the disease or condition, or symptoms thereof is central diabetes insipidus. 24. The method of claim 1, wherein the disease or condition, or symptoms thereof is primary nocturnal enuresis. 25. The method of claim 1, wherein the disease or condition, or symptoms thereof is nocturnal enuresis. 26. The method of claim 25, wherein the method further comprises administering an additional therapy or treatment regimen. 27. The method of claim 26, wherein the additional therapy or treatment regimen comprises an anticholinergic medication. 28. The method of claim 1, wherein the liquid pharmaceutical composition is administered to the subject orally or through a nasogastric, jejunostomy, or gastrostomy tube. 29. The method of claim 1, wherein the subject has an age of less than 18 years old.